1. Define cardiovascular-kidney-metabolic (CKM) syndrome and its various stages.

2. Justify the role of the Predicting Risk of Cardiovascular Disease Events (PREVENT) equations in the

framework of CKM syndrome.

3. Design a treatment plan for individuals with different stages of CKM syndrome.

1. Distinguish the differences in treatments for the management of overweight and obesity.

2. Assess and design a pharmacotherapy plan for a patient classified as an individual with overweight or obesity

given patient-specific factors.

3. Devise monitoring values to determine the efficacy and safety of anti-obesity (AOM) pharmacotherapy.

4. Evaluate available literature to bridge gaps in knowledge with emerging evidence.

1. Design glycemic goals and a monitoring plan for patients at risk of glycemic excursions in the hospital.

2. Devise a safe and effective glycemic management strategy for patients with hyperglycemia in the hospital.

3. Develop a comprehensive plan to identify and treat patients with hyperglycemic emergencies in the hospital.

4. Construct an approach to keep patients living with diabetes safe during transitions from the hospital setting.

1. Design glycemic goals and a monitoring plan for patients at risk of glycemic excursions in the hospital.

2. Devise a safe and effective glycemic management strategy for patients with hyperglycemia in the hospital.

3. Develop a comprehensive plan to identify and treat patients with hyperglycemic emergencies in the hospital.

4. Construct an approach to keep patients living with diabetes safe during transitions from the hospital setting.

1. Distinguish among the various diabetes technology options.

2. Identify optimal candidates for insulin pump use.

3. Develop a treatment plan based on the insulin pump data.

1. Justify the rationale for transitioning from Cockcroft-Gault estimated creatinine clearance (C-G eCrCl) to nonrace-

based estimated glomerular filtration rate (eGFR) for clinical decision-making.

2. Apply methods for converting standardized eGFR (mL/min/1.73 m²) to body surface area (BSA)-adjusted

eGFR (mL/min) for individualized medication dosing.

3. Distinguish clinical indications for incorporation of cystatin C into the eGFR calculation for medication-related

decisions.

4. Develop strategies to improve clinician adoption of eGFR equations and address health care system barriers

to accessing, reporting, and integrating BSA-adjusted eGFR into medication-related decisions.

1. Assess patient-specific challenges to managing chronic comorbidities in patients with end-stage kidney

disease (ESKD) receiving kidney replacement therapy (KRT).

2. Evaluate an antihypertensive medication regimen for safety and efficacy optimization in a patient receiving

KRT.

3. Design a heart failure medication management plan for a patient receiving KRT.

4. Adjust a medication management plan for a patient with diabetes progressing from chronic kidney disease to

ESKD starting KRT.

1. Assess factors that influence contraceptive choice.

2. Evaluate the effect of reproductive health policies on contraceptive access.

3. Analyze updates to the US Medical Eligibility Criteria for Contraceptive Use and US Selected Practice

Recommendations for Contraceptive Use.

4. Compare and contrast the efficacy and safety of available methods of contraception.

5. Develop a contraceptive plan that considers patient-specific factors.

1. Given patient-specific factors, design optimal pharmacotherapy for a cisgender patient with menopause.

2. Develop a patient-specific monitoring and reassessment plan for cisgender patients receiving medication

therapies for menopausal symptoms.

3. Given patient-specific factors, design an optimized therapy plan for managing hypogonadism in a cisgender

patient.

4. Develop a patient-specific monitoring and reassessment plan for cisgender patients receiving testosterone for

the treatment of hypogonadism.